Absci Shares Fall on Wider 4Q Loss, Lower Revenue
By Connor Hart
Shares of Absci fell after the company widened its loss and logged lower revenue in the fourth quarter.
The stock declined 12%, to $2.64, in premarket trading Wednesday. Through Tuesday's close, shares are up 3.8% over the past year.
The biopharmaceutical company late Tuesday posted a widened loss of $29.6 million for its three months ended Dec. 31, compared with a loss of $29 million a year earlier. The quarterly loss came in at 20 cents a share, compared with analyst expectations for a loss of 18 cents a share, according to FactSet.
Revenue slipped 2.3% to $650,000, missing the $1.4 million that Wall Street modeled.
Founder and CEO Sean McClain said Absci made progress advancing its in-development therapies over the past year, noting that the company is implementing artificial intelligence to design therapeutics faster and cheaper than the broader industry.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
March 25, 2026 06:51 ET (10:51 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States